Active treatment for Obsessive-Compulsive Disorder

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Obsessive-Compulsive Disorder+1 More
Light therapy - Behavioral
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this study is to examine the effect of a light-based circadian treatment on OCD symptoms in adults with OCD and late bedtimes. This study will have important implications for understanding the role of circadian rhythms in the etiology and treatment of OCD.

Eligible Conditions
  • Obsessive-Compulsive Disorder

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Obsessive-Compulsive Disorder

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 5 weeks

3 weeks
Circadian phase
Obsessive-Compulsive Inventory-Revised score
5 weeks
Yale-Brown Obsessive-Compulsive Scale score

Trial Safety

Safety Progress

1 of 3

Other trials for Obsessive-Compulsive Disorder

Trial Design

2 Treatment Groups

Active treatment
1 of 2
Control treatment
1 of 2
Active Control
Non-Treatment Group

30 Total Participants · 2 Treatment Groups

Primary Treatment: Active treatment · Has Placebo Group · N/A

Active treatment
Behavioral
ActiveComparator Group · 1 Intervention: Light therapy · Intervention Types: Behavioral
Control treatmentPlaceboComparator Group · 2 Interventions: Light therapy, Placebo light therapy · Intervention Types: Behavioral, Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 5 weeks

Who is running the clinical trial?

University of Colorado, BoulderLead Sponsor
108 Previous Clinical Trials
27,625 Total Patients Enrolled
Rebecca C Cox, PhDPrincipal InvestigatorUniversity of Colorado, Boulder

Eligibility Criteria

Age 18 - 65 · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are awake at or after 0100.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 21st, 2021

Last Reviewed: October 11th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.